Trends in disease-modifying therapy use in patients with multiple sclerosis using a 10-year population-based cohort study in France - Faculté de droit - unités de recherche Accéder directement au contenu
Article Dans Une Revue Expert Review of Neurotherapeutics Année : 2022

Trends in disease-modifying therapy use in patients with multiple sclerosis using a 10-year population-based cohort study in France

Résumé

Background: The availability of new disease-modifying therapies (DMTs) for patients with multiple sclerosis (MS) provides an opportunity for improving outcomes but makes disease management more complex. Our study aimed to describe changes in therapeutic practices over the period 2009-2018 and measure the impact of the arrival of oral DMTs on the use of injectable DMTs.Methods: Data were extracted from a representative 1/97 sample of the French population covered by the healthcare insurance system. Study period was set from 1 January 2009 to 31 December 2018. Four periods of MS identification were defined (before 2009, 2009-2011, 2012-2015 and 2016-2018).Results: Overall, 1,508 patients with MS were included, of whom 876 (58.1%) were treated at least once over the study period. Untreated patients were older and had more comorbidities than treated ones. First-line DMTs were the most frequent initial DMT (78.5%) and a shift has operated from injectable to oral drugs over time. The proportion of patients receiving several DMTs increased with the number of available drugs. End 2018, beta interferon, glatiramer acetate, teriflunomide, dimethylfumarate, fingolimod and natalizumab shared nearly equal parts.Conclusions: This study provides valuable insights into the real-world use of DMTs and changes that have operated over time.
Fichier principal
Vignette du fichier
S. Leblanc -Trends in disease-modifying therapy.pdf (1.58 Mo) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-03629848 , version 1 (23-06-2022)

Licence

Paternité - Pas d'utilisation commerciale

Identifiants

Citer

Soline Leblanc, Mathilde Lefort, Emmanuelle Le Page, Laure Michel, Emmanuelle Leray. Trends in disease-modifying therapy use in patients with multiple sclerosis using a 10-year population-based cohort study in France. Expert Review of Neurotherapeutics, 2022, 22 (5), pp.411-418. ⟨10.1080/14737175.2022.2061950⟩. ⟨hal-03629848⟩
94 Consultations
37 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More